Table 6 Summary of fluid balance data (mL)
Remogliflozin etabonate dose | ||||||
|---|---|---|---|---|---|---|
Placebo | 20 mg | 50 mg | 150 mg | 500 mg | 1000 mg | |
Healthy Subjects | (n = 10) | (n = 8) | (n = 8) | (n = 8) | (n = 8) | (n = 8) |
-24 h to pre-dose | -462 (605) | -460 (1311) | -338 (525) | -512 (731) | -278 (1250) | -126 (798) |
0–12 h post-dose | 163 (668) | 243 (1161) | -570 (582) | -86 (909) | -159 (531) | -273 (331) |
12–24 h post-dose | -739 (423) | -581 (387) | -551 (530) | -564 (478) | -424 (334) | -495(367) |
T2DM subjects | n = 6 | n = 6 | n = 6 | |||
-24 h to pre-dose | -312 (457) | -504 (294) | 188 (1879) | |||
0–12 h post-dose | 569 (400) | -78(433) | -29 (749) | |||
12–24 h post-dose | -908 (524) | -803 (658) | -1088(679) | |||